Related references
Note: Only part of the references are listed.Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis
Darren Plant et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis
Claudio Carini et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients
John C. Taylor et al.
PHARMACOGENOMICS JOURNAL (2018)
Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission
Shinya Tasaki et al.
NATURE COMMUNICATIONS (2018)
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
Amit V. Khera et al.
NATURE GENETICS (2018)
Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis
Jonathan Massey et al.
PHARMACOGENOMICS JOURNAL (2018)
Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS)
Jamie C. Sergeant et al.
ARTHRITIS RESEARCH & THERAPY (2018)
High frequency of antidrug antibodies and OPEN ACCESS association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort
Meghna Jani et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis
Mari Kihara et al.
CLINICAL RHEUMATOLOGY (2017)
Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis
S. Bek et al.
PHARMACOGENOMICS JOURNAL (2017)
Integrative Approaches to Understanding the Pathogenic Role of Genetic Variation in Rheumatic Diseases
Vincent A. Laufer et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2017)
Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis Results From the Norfolk Arthritis Register
James M. Gwinnutt et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register
Jennifer H. Humphreys et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis
Darren Plant et al.
ARTHRITIS & RHEUMATOLOGY (2016)
The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO
Else Helene Ibfelt et al.
CLINICAL EPIDEMIOLOGY (2016)
Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis
Mikael Brink et al.
ARTHRITIS RESEARCH & THERAPY (2016)
A HPLC-SRM-MS based method for the detection and quantification of methotrexate in urine at doses used in clinical practice for patients with rheumatological disease: a potential measure of adherence
J. Bluett et al.
ANALYST (2015)
Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response
Sebastien Viatte et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Anti-carbamylated Protein Antibodies Are Present Prior to Rheumatoid Arthritis and Are Associated with Its Future Diagnosis
Ryan W. Gan et al.
JOURNAL OF RHEUMATOLOGY (2015)
The support of human genetic evidence for approved drug indications
Matthew R. Nelson et al.
NATURE GENETICS (2015)
Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis
Jana Hurnakova et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage
Mikael Brink et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis
Meghna Jani et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial
Karen Hambardzumyan et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
James Bluett et al.
RHEUMATOLOGY (2015)
How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)?
H. Wadstrom et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2015)
Genetics of rheumatoid arthritis contributes to biology and drug discovery
Yukinori Okada et al.
NATURE (2014)
Genetic and epigenetic predictors of responsiveness to treatment in RA
Darren Plant et al.
NATURE REVIEWS RHEUMATOLOGY (2014)
Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis
Lis Cordingley et al.
ARTHRITIS CARE & RESEARCH (2014)
Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: Results from the Swiss SCQM registry
Pascal Zufferey et al.
JOINT BONE SPINE (2013)
Genetics and epigenetics of rheumatoid arthritis
Sebastien Viatte et al.
NATURE REVIEWS RHEUMATOLOGY (2013)
Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis
Michael Centola et al.
PLOS ONE (2013)
Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis
Jing Cui et al.
PLOS GENETICS (2013)
Genetic predisposition of the severity of joint destruction in rheumatoid arthritis: a population-based study
Rachel Knevel et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort
Darren Plant et al.
ARTHRITIS AND RHEUMATISM (2012)
High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis
Steve Eyre et al.
NATURE GENETICS (2012)
Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis
Soumya Raychaudhuri et al.
NATURE GENETICS (2012)
MOPED: Model Organism Protein Expression Database
Eugene Kolker et al.
NUCLEIC ACIDS RESEARCH (2012)
Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0
Loreto Carmona et al.
RHEUMATOLOGY (2011)
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis
C. Potter et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis
Kunihiro Nishimura et al.
ANNALS OF INTERNAL MEDICINE (2007)
LRP1 Functions as an Atheroprotective Integrator of TGFβ and PDGF Signals in the Vascular Wall: Implications for Marfan Syndrome
Philippe Boucher et al.
PLOS ONE (2007)
Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis:: results from the British Society for Rheumatology Biologics Register
K. L. Hyrich et al.
RHEUMATOLOGY (2006)
Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis
S Rantapää-Dahlqvist et al.
ARTHRITIS AND RHEUMATISM (2003)